Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Cue Biopharma, Inc.

industry_trends_dossier

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

financial_statements

network_onboarding

signals

swot_dossier

news_advanced

news_impact_assignment_basic

news_impact_assignment_advanced

news_processing_basic

news_processing_advanced

peers

valuation

customer_profile

news_basic

NASDAQ:CUE

Cue Biopharma, Inc.

Last Close

2.18

08/05 20:00

Market Cap

119.13M

Beta: 2.00

Volume Today

261.07K

Avg: 186.50K

PE Ratio

−2.14

PFCF: −2.73